Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA

Hepatology

Volumn 49, Issue 6, 2009, Pages 2080-2086

  Seok, Jung Im ^a   Lee, Dong Kuck ^a   Lee, Chang Hyeong ^a   Park, Min Su ^b   Kim, Sun Young ^c   Kim, Hyang Sook ^d   Jo, Hee Young ^d   Lee, Chang Hun ^d   Kim, Dae Seong ^d  

^a Catholic University of Daegu   (South Korea)

^b Yeungnam University College of Medicine   (South Korea)

^c Kyungpook National University Hospital   (South Korea)

^d Pusan National University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CLEVUDINE; CREATINE KINASE; CYTOCHROME C OXIDASE; LACTATE DEHYDROGENASE; LACTIC ACID; MITOCHONDRIAL DNA; PYRUVIC ACID; REVOVIR; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DNA CONTENT; DRUG WITHDRAWAL; ELECTROMYOGRAPHY; FATTY LIVER; FEMALE; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LACTATE BLOOD LEVEL; LACTATE DEHYDROGENASE BLOOD LEVEL; LONG TERM CARE; MALE; MITOCHONDRIAL DNA DEPLETION; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE MITOCHONDRION; MUSCLE NECROSIS; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NAUSEA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SKELETAL MUSCLE; TREATMENT DURATION;

ADULT; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; CHRONIC DISEASE; DNA, MITOCHONDRIAL; FEMALE; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; MITOCHONDRIAL MYOPATHIES; TIME FACTORS;

EID: 68649086002     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22959     Document Type: Article

References (30)

1. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119:172-180.
2. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. HEPATOLOGY 2001;33:1527-1532.
3. Xu XW, Chen YG. Current therapy with nucleoside/nucleotide analogs for patients with chronic hepatitis B. Hepatobiliary Pancreat Dis Int 2006; 5:350-359.
4. Honkoop P, de Man R, Heijtink R, Schalm S. Hepatitis B reactivation after lamivudine. Lancet 1995;346:1156-1157.
5. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995;333:1099-1105.
6. Yoo BC, Kim JH, Kim TH, Koh KC, Um SH, Kim YS, et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. HEPATOLOGY 2007;46:1041-1048.
7. Medical Research Council. Aids to Examination of the Peripheral Nervous System. Memorandum No. 45. London, England: Her Majesty's Stationary Office; 1976.
8. Mariotti C, Castellotti B, Pareyson D, Testa D, Eoli M, Antozzi C, et al. Phenotypic manifestations associated with CAG-repeat expansion in the androgen receptor gene in male patients and heterozygous females: A clinical and molecular study of 30 families. Neuromuscul Disord 2000;10: 391-397.
9. Oh SJ. Clinical Electromyography: Nerve Conduction Studies. Baltimore, MD: Williams & Wilkins; 1998.
10. Dubowitz V, Brooke MH. Muscle Biopsy: A Modern Approach. London, England: W.B. Saunders; 1973.
11. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16: 1215.
12. Stuyver LJ, Lostia S, Adams M, Mathew JS, Pai BS, Crier J, et al. Antiviral activities and cellular toxicities of modified 2′,3′-dideoxy-2′,3′-didehy-drocytidine analogues. Antimicrob Agents Chemother 2002;46:3854-3860.
13. Jónsson SR, LaRue RS, Stenglein MD, Fahrenkrug SC, Andrésdóttir V, Harris RS. The restriction of zoonotic PERV transmission by human APOBEC3G. PLoS ONE 2007;2:e893.
14. Korba BE, Furman PA, Otto MJ. Clevudine: A potent inhibitor of hepatitis B virus in vitro and in vivo. Expert Rev Anti Infect Ther 2006;4:549-561.
15. Peek SF, Cote PJ, Jacob JR, Toshkov IA, Hornbuckle WE, Baldwin BH, et al. Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax). HEPATOLOGY 2001;33:254-266.
16. Chariot P, Gherardi R. Myopathy and HIV infection. Curr Opin Rheumatol 1995;7:497-502.
17. Masanés F, Barrientos A, Cebrián M, Pedrol E, Miró O, Casademont J, et al. Clinical, histological and molecular reversibility of zidovudine myopathy. J Neurol Sci 1998;159:226-228.
18. Lewis W, Simpson JF, Meyer RR. Cardiac mitochondrial DNA polymerase-gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine. Circ Res 1994;74:344-348.
19. Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: An integrated cellular perspective. Nat Rev Drug Discov 2003; 2:812-822.
20. Tyzeka (Telbivudine) Tablets. Cambridge, MA: Idenix Pharmaceuticals; 2006.
21. Bayrakci US, Baskin E, Ozcay F, Ozdemir BH, Karakayali H, Haberal M. Renal Fanconi syndrome and myopathy after liver transplantation: drug-related mitochondrial cytopathy? Pediatr Transplant 2008;12:109-112.
22. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al., for the Globe Study Group. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-2588.
23. Adani GL, Baccarani U, Risaliti A, Bresadola F, Della Rocca G, Viale P. Rhabdomyolysis due to lamivudine administration in a liver transplant recipient. Am J Transplant 2005;5:634.
24. Yahagi K, Ueno Y, Mano Y, Shimosegawa T. Rhabdomyolytic syndrome during the lamivudine therapy for acute exacerbation of chronic type B hepatitis. Liver Transpl 2002;8:1198-1199.
25. Semino-Mora C, Leon-Monzon M, Dalakas MC. Mitochondrial and cellular toxicity induced by fialuridine in human muscle in vitro. Lab Invest 1997;76:487-495.
26. Pai SB, Liu SH, Zhu YL, Chu CK, Cheng YC. Inhibition of hepatitis B virus by a novel L-nucleoside, 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil. Antimicrob Agents Chemother 1996;40:380-386.
27. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000;22:685-708.
28. Scruggs ER, Dirks Naylor AJ. Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy. Pharmacology 2008;82:83-88.
29. Capasso M, Di Muzio A, Comar M, Robuffo I, Gambi A, Crovella S, et al. The association of chronic hepatitis B and myopathy. Neurology 2006;67: 1467-1469.
30. Sieb JP. Myopathies due to drugs, toxins, and nutritional deficiency. In: Engel AG, ed. Myology. 3rd ed. New York, NY: McGraw-Hill; 2004: 1693-1712.